Startups
Atossa Therapeutics Inc., is developing locally-administered pharmaceuticals for the treatment of pr
Overview
Location
United States
Phone
+1 206-588-0256
Mentions in press and media 9
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 27, 2025 | Harbour BioMed Reports 2025 Interim Results | CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of ... |
| Apr 10, 2025 | Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer | CAMBRIDGE, Mass., April 10, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to ITM), ranging from target validation and antibody discovery through preclini... |
| Mar 12, 2024 | Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors | |
| Mar 6, 2024 | Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting | |
| Dec 8, 2022 | Tech Moves: Ex-RealSelf leader joins Oggvo; ex-Adaptive CFO lands at Capella Space; and more | Maureen Ezekwugo. (Oggvo Photo) — Maureen Ezekwugo is now CEO of Oggvo, which develops customer review management software for small- to medium-sized businesses. Ezekwugo was previously at Seattle-based cosmetic treatment review platform Re... |
| Nov 7, 2022 | Tech Moves: Allen Institute hires COO; DexCare adds CTO; and more | Chris Beaudoin, the incoming chief operating officer at the Allen Institute. (Allen Institute Photo) — The Allen Institute appointed Chris Beaudoin as its new chief operations officer. Beaudoin was previously chief operating officer at Swed... |
| Jun 23, 2021 | A tiny biotech company focused on breast cancer treatments has soared 29% amid Reddit hype | Atossa Therapeutics rallied 29% Tuesday on hype from retail traders on Reddit. Redditors cheered that the company will soon be included on the Russell 2000 and 3000 indexes. The Seattle-based biopharmaceutical is focused on developing its b... |
| Jun 9, 2021 | ATOSSA THERAPEUTICS, INC. Atossa Therapeutics Announces Final Data from Phase 2 Endoxifen Breast Cancer Study Primary Endpoint Met: 65.1% Reduction in Biomarker Ki-67; Secondary Endpoint Met: Endoxifen Safe and Well Tolerated | SEATTLE, June 09, 2021 - Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast canc... |
Reviews 0
FAQ about Atossa Therapeutics
What has the press written about Atossa Therapeutics?
Parsers VC has collected 9 articles mentioning Atossa Therapeutics, among them “Harbour BioMed Reports 2025 Interim Results” (Aug 27, 2025) and “Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer” (Apr 10, 2025).
Is Atossa Therapeutics still active?
Yes, Atossa Therapeutics is active; its latest activity on Parsers VC dates from Jun 12, 2026.